York expands through product acquisitions
This article was originally published in Scrip
Executive Summary
The UK-based dermatology company York Pharmahas signed a licensing deal to market two wound infection treatments, Flammazine and Flammacerium, fromSolvay Pharmaceuticals. It has also agreed a financing package to fund the acquisition and provide working capital.